Ebglyss FDA approval intensifies competition in atopic dermatitis market: GlobalData EP News Bureau Oct 9, 2024 Eli Lilly’s Ebglyss enters the US market, poised to challenge established therapies like Dupixent and Adbry/Adtralza in the atopic…
FDA rejection to delay Lebrikizumab chances to enter atopic dermatitis market: GlobalData EP News Bureau Oct 31, 2023 GlobalData currently expects Lilly to resubmit lebrikizumab’s BLA in Q4 2023
